Logiscreen

Exagen Inc

$4.29
Market Cap 103.19M
ROE -113.5%
Gross Margin 59.0%
Debt/Equity 1.9
Current Ratio 3.5
Revenue QoQ 11.7%
EPS QoQ -0.2%
F-Score 3

About

Exagen Inc. is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, Calif., Exagen’s mission is to provide clarity in autoimmune disease decision making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE ® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s disease earlier and with greater accuracy. Exagen’s laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management.

Exchange
NASDAQ
Sector
Healthcare
Industry
Diagnostics & Research

Sector context

Healthcare

Undervalued

Trading at a discount to sector peers

P/E
-5.71
vs median 31.50
P/B
7.98
vs median 2.17
ROE
-1.14
vs median 0.09

Lower quality - review fundamentals carefully

Small-cap company with higher volatility

Similar companies

Primary metric
Overlay metric
Loading chart data...
Fetching latest financial metrics